You are here

  • Home
  • Archive
  • Volume 76, Issue 1
  • Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)

Article Text

Article menu
Download PDFPDF
Clinical and epidemiological research
Concise report
Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)
  1. Vibeke Strand1,
  2. Philip Mease2,
  3. Laure Gossec3,
  4. Ori Elkayam4,
  5. Filip van den Bosch5,
  6. James Zuazo6,
  7. Luminita Pricop7,
  8. Shephard Mpofu6
  9. on behalf of the FUTURE 1 study group
  1. 1Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA
  2. 2Swedish Medical Center, University of Washington, Seattle, Washington, USA
  3. 3Department of Rheumatology, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Paris, France
  4. 4Department of Rheumatology, Tel Aviv Medical Center, “Sackler” Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  5. 5Department of Rheumatology, University of Ghent, Ghent, Belgium
  6. 6Novartis Pharma AG, Basel, Switzerland
  7. 7Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
  1. Correspondence to Professor Vibeke Strand, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto CA 94034, USA; vstrand{at}stanford.edu

Abstract

Objective To evaluate the effect of secukinumab on patient-reported outcomes (PROs) in subjects with active psoriatic arthritis (PsA) in the FUTURE 1 study.

Methods Subjects were randomised 1:1:1 to receive intravenous (i.v.) secukinumab 10 mg/kg at weeks 0, 2 and 4 followed by subcutaneous secukinumab 150 or 75 mg every 4 weeks or matching placebo until week 24.

Results At week 24, subjects receiving secukinumab i.v.→150 mg or i.v.→75 mg reported greater least squares mean changes from baseline than those receiving placebo in patient global assessment of disease activity (−20.6 and −20.0 vs −7.4, respectively), patient assessment of pain (−20.8 and −20.4 vs −6.7), psoriatic arthritis quality of life (−3.5 and −3.2 vs −0.4), Dermatology Life Quality Index (−8.8 and −7.9 vs 0.7); p<0.0001 vs placebo for both secukinumab groups for above PROs and Functional Assessment of Chronic Illness Therapy-Fatigue (6.74 (p<0.05 vs placebo) and 6.03 vs 4.00); all of which well exceeded minimum clinically important differences.

Conclusions In subjects with PsA, secukinumab treatment resulted in clinically meaningful improvements in global disease activity, pain, generic and disease-specific measures of health-related quality of life and fatigue.

Trial registration number NCT01392326; Results.

  • Psoriatic Arthritis
  • Treatment
  • Quality Indicators
  • Patient perspective

https://doi.org/10.1136/annrheumdis-2015-209055

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Handling editor Tore K Kvien

    • Parts of the patient-reported outcome data from the FUTURE 1 trial were previously presented at the American College of Rheumatology (ACR) annual meeting, 15–19 November 2014, Boston, Massachusetts, USA

    • Contributors All authors had access to the data, contributed to its interpretation and collaborated in the development of the manuscript. All authors critically reviewed and provided feedback on subsequent versions. All authors made the decision to submit the manuscript for publication and vouch for the accuracy and completeness of the data and fidelity of this report to the study protocol.

    • Funding The study was sponsored by Novartis Pharma AG, Basel, Switzerland and designed by the scientific steering committee and Novartis personnel. Medical writing support was funded by Novartis.

    • Competing interests VS has received consulting fees from Abbvie, Amgen, Bristol-Myers Squibb, Celgene, Genentech/Roche, Janssen, Lilly, Merck, Novartis, Pfizer and UCB. PM has received research grants, consultation fees and/or speaking fees from Abbvie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer and UCB. LG has received lecture/consultancy honoraria from Abbvie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis, Pfizer, Roche and UCB. FvdB has received speaker or consultancy fees from Abbvie, Bristol-Myers Squibb, Celgene, Janssen, Lilly, Merck, Novartis, Pfizer and UCB. JZ, LP and SM are employees of Novartis.

    • Ethics approval The study protocol was approved by the institutional review board or ethics committees at each centre.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data sharing statement The study protocol can be made available on request.